Subject Index

ACE inhibitors, see Angiotensin-converting enzyme inhibitors
Advanced glycation end products (AGEs)  
diet effects on inflammation 78  
hemodiafiltration removal 180
Alkaline phosphatase, chronic kidney disease-mineral and bone disorder biomarker 225
Analgesics, Dialysis Outcomes and Practice Patterns Study findings 53
Anemia  
hemoglobin  
cycling 242, 243  
target in chronic kidney disease 241, 242
pure red cell aplasia with erythropoiesis-stimulating agents 243, 244
red blood cell lifespan determination  
  breath carbon monoxide 252, 253  
  chromium-51 labeling 252
effects on erythropoietin-stimulating agent therapy 250–252
overview 248, 249
survival in renal failure 249
vitamin E studies in dialysis patients 93–95
Angiography, preoperative fistula evaluation 24, 25
Angiotensin-converting enzyme (ACE) inhibitors, Dialysis Outcomes and Practice Patterns Study findings 50
Antihypertensive agents, Dialysis Outcomes and Practice Patterns Study findings 50
Arterial blood pressure, biofeedback-driven dialysis 205, 206
Arteriovenous fistula (AVF)  
access dysfunction detection 13, 14
advantages 12
physical examination monitoring 14–16
preoperative evaluation  
  angiography 24, 25
  ultrasonography  
    arterial assessment 25, 26
    venous assessment 27
prevalence trends in vascular access 13
stenosis, see Vascular access surveillance
  blood flow 18, 19
  intra-access static pressures 16, 17
  recirculation 17
Aspirin, Dialysis Outcomes and Practice Patterns Study findings 52
Atherosclerosis, oxidative stress in pathogenesis 134–136
Bicarbonate, dialysate composition 10
Biofeedback-driven dialysis  
arterial pressure biofeedback 205, 206
biochemical monitoring and control 206, 207
blood volume biofeedback 200–203
body temperature biofeedback 203–205
integrated adaptive control 207, 208
Bioimpedance, see Whole-body impedance spectroscopy
Biosimilar
  definition 261
  erythropoietin 244, 245, 264–267, 269
  generic drug comparison
    immunogenicity 263, 264
    manufacturing differences 263
    product differences 262, 263
    regulation of evaluation 267–269
Bisphosphonates, vascular calcification effects 230
Blood volume monitoring (BVM)
  advantages 124
  biofeedback-driven dialysis 200–203
  clinical outcomes 121–123
  overview 119, 120
  study design in diabetes 120, 121
Body composition, assessment in hemodialysis patients 109–113
Body mass index (BMI)
  correlation with hemodialysis outcomes 108–113
  urea distribution volume relationship 112, 113
Body temperature, biofeedback-driven dialysis 203–205
Body transfer resistance
  solute mass transfer 181
  treatment time effects 181, 182
Bone mineral density (BMD), monitoring in renal patients 226
B-type natriuretic peptide (BNP)
  actions 69, 70
  physiology 68, 69
  renal insufficiency effects 70–72
  therapeutic prospects 73, 74
Calcium
  absorption 211, 212
  chronic kidney disease-mineral and bone disorder biomarker 225
  dialysate composition 9, 10
  hemodialysis flux kinetics 213, 214
  intake 211
  mineral metabolism disorders and outcomes in renal patients
  correction of causal factors and secondary event prevention 218–220
  epidemiology 217, 218
  pathophysiology 216, 217
  time-related plausibility between causal factors and secondary events 218
  phosphate binders 235, 236
Cardiovascular disease
  non-traditional risk factors 223
  risks in chronic kidney disease 63–66
Central venous catheter (CVC)
  catheter type and site 41
  complications 40, 42
  continuous quality improvement care 45
  duration of use in hemodialysis patients 44
  indications in hemodialysis 40, 41
  insertion 41
  monitoring and maintenance 49, 59
  nursing and care staff 42, 43
  patient education 43
  prevalence in hemodialysis patients 39
  risk factors 44, 45
Chronic kidney disease (CKD)
  cardiovascular disease risks 63–66
  insulin resistance correlation 139
  mortality of dialysis patients 138
Chronic kidney disease-mineral and bone disorder (CKD-MBD)
  biomarkers
    alkaline phosphatase 225
    calcium 225
    parathyroid hormone 224, 225
    phosphorus 225
    vitamin D (calcidiol) 225
  bone biopsy and histological parameters 224
  definition 224
  management
    hyperphosphatemia control 227, 228
    overview 227
    secondary hyperparathyroidism control 229, 230
    soft tissue calcification imaging 225–227
Cinacalcet, secondary hyperparathyroidism control 214, 229, 238
Computed tomography (CT), vascular calcification 226
*p-Cresol, hemodiafiltration removal 180
Cross-membrane flux, middle-molecule removal 179

Daily hemodialysis
  HEMO Study of dose 146
  historical perspective 147, 148
  London Study of more frequent hemodialysis 148–150
  prospects for more frequent dialysis 152 rationale 146, 147

Dialysate composition
  acid buffering and bicarbonate 10
calcium 9, 10
potassium
  arrhythmia relationship 9
  concentration 9
sodium
  concentration 7, 8
  conductivity kinetic modeling 8, 9

Dialysis membrane, see Membrane

Dialysis Outcomes and Practice Patterns Study (DOPPS)
  medication use and outcome findings
    analgesics 53
    antihypertensive agents 50
    aspirin 52
    gastro-protective agents 52
    multivitamins 53
    overview 48, 49
    statins 51, 52
    study design 49
  treatment time analysis 155–159, 176, 177

Distribution loop, contaminant control 2–4
DNA methylation, see Epigenetics
Dry weight, assessment 100–102, 115–118

Endothelial function, dialysis patients 84–87

Epigenetics
  epigenotype manipulation 59, 60
  overview 55, 56
  techniques for study 56, 57
  uremia and epigenotype 57–59

Erythropoietin (EPO)
  biosimilars 244, 245, 264–267
  erythropoiesis-stimulating agent
    prospects 256, 259
    fusion polymers 257
  gene expression regulation 259
  gene therapy 258, 259
  high-molecular-weight erythropoietins 256, 257
  mimetic antibody fusion peptide 257
  pure red cell aplasia induction 243, 244
  red blood cell lifespan effects on erythropoietin-stimulating agent therapy 250–252
  resistance and body composition 109
  small-molecule erythropoiesis-stimulating agents 258

Folic acid
  diet effects on inflammation 79
  epigenetics and levels 58, 59

Gene therapy, erythropoietin 258, 259

Hemodiafiltration (HDF)
  clearance performance 179–181
  cross-membrane flux and middle-molecule removal 179
  inflammation
    chronic inflammation 186, 187
    RISCAVID Study 187, 188
  online hemodiafiltration
    conventional mode 193, 194
    disinfection and microbial monitoring 195, 196
    double high-flux hemodialysis 194
    hygiene rules 193
    mid-dilution mode 195
    paired hemofiltration 194
    prescription 195
    push/pull mode 194
    technical prerequisites 192, 193
    vascular access 193

Hemodialysis frequency, see Daily hemodialysis

Hemodialysis treatment time
  body transfer resistance effects 180, 181
effects on patient outcome
Dialysis Outcomes and Practice Patterns Study 155–159, 176, 177
National Cooperative Dialysis Study 175
history of study 154, 155
nutrition effects 158
optimization 159, 160
phosphate balance 159
survival findings 155, 156
ultrafiltration rate 156–158
Hemoglobin
cycling 242, 243
target in chronic kidney disease 241, 242
HEMO Study
frequency of hemodialysis findings 146
National Cooperative Dialysis Study
dosing controversy 172, 173
observational study reconciliation 173–175
treatment time studies 158
uremic toxicity and outcomes 128, 129, 178, 179
Histamine receptor antagonists, Dialysis Outcomes and Practice Patterns Study findings 52
Hollow-fiber membrane, see Membrane
Homocysteine
epigenetics and levels 57, 58
hemodiafiltration removal 180
Hydration, see Overhydration
Hyperparathyroidism, see Secondary hyperparathyroidism
Hyperphosphatemia, control 227, 228
Inflammation
epigenetics and homocysteine levels 57, 58
hemodiafiltration
chronic inflammation 186, 187
RISCAVID Study 187, 188
insulin resistance and chronic kidney disease 140
nutrition interactions
diet effects on inflammation 78–81
inflammation effect on nutritional state 77, 78
oxidative stress 84
pathogenesis 77
Insulin resistance
chronic kidney disease correlation 139
factors affecting in chronic kidney disease 140, 141
protein turnover 141–143
Kt/V
dialysis prescription 169
National Cooperative Dialysis Study
dosing controversy 169–172
Lanthanum carbonate
hyperphosphatemia control 228
secondary hyperparathyroidism control 236, 237
Leptin, hemodiafiltration removal 180
Mediterranean diet, effects on inflammation 80
Membrane
cross-membrane flux and middle-molecule removal 179
dialyzer classification by membrane composition
modified cellulosic dialyzers 165
synthetic dialyzers 165, 166
dialyzer classification by membrane composition (continued)
unmodified cellulosic dialyzers 164, 165
hollow-fiber membrane characteristics
dimensions 162, 163
non-membrane-related determinants of performance 164
pore properties 167, 168
surface area 163
vitamin E coating
clinical studies 92
mechanisms of action 92, 93
synthetic membrane biocompatibility 96
Monocyte, endothelial function in dialysis patients 84–87
Multivitamins, Dialysis Outcomes and Practice Patterns Study findings 53
Myeloperoxidase (MPO)
inflammation and oxidative stress role in uremia 136
oxidative stress role 133, 134

NADPH oxidase, oxidative stress role 133
National Cooperative Dialysis Study (NCDS)
dosing controversy 169–172
treatment time effects on patient outcome 175

Obesity paradox, see Body mass index
Online hemodiafiltration, see Hemodiafiltration
Online intradialytic monitoring, principles 200

Overhydration
consequences of sodium excess and overhydration 102–104
dry weight assessment 100–102, 115–118
epidemiology in dialysis patients 99, 100
modulation 104–106
whole-body impedance spectroscopy studies 115–118

Oxidative stress
atherosclerosis pathogenesis role 134–136
inflammation and endothelial function in dialysis 84
pathways 132–134
prevalence in kidney disease 135, 136
vitamin E therapy
anemia studies 93–95
dialysis membrane coating clinical studies 92
mechanisms of action 92, 93
synthetic membrane biocompatibility 96
dietary supplementation 90–92
low-density lipoprotein oxidation inhibition 90

Parathyroid hormone (PTH)
chronic kidney disease-mineral and bone disorder biomarker 224, 225
hyperparathyroidism, see Secondary hyperparathyroidism

Percutaneous balloon angioplasty, vascular access stenosis 31–33

Phosphate
absorption 211
calcium-based binders 235, 236
chronic kidney disease-mineral and bone disorder biomarker 225
hemodiafiltration removal 180
hemodialysis flux kinetics 212, 213
treatment time and balance 159
hyperphosphatemia control 227, 228
intake 211
mineral metabolism disorders and outcomes in renal patients
correction of causal factors and secondary event prevention 218–220
epidemiology 217, 218
pathophysiology 216, 217
time-related plausibility between causal factors and secondary events 218

Physical examination, arteriovenous fistula 14–16

Potassium, dialysate
arrhythmia relationship 9
concentration 9

Procainamide, DNA methyltransferase inhibition 59

Protein turnover
insulin resistance studies 142, 143
insulin role 142

Proton pump inhibitors, Dialysis Outcomes and Practice Patterns Study findings 52

Pure red cell aplasia (PRCA), erythropoiesis-stimulating agent induction 243, 244

Reactive oxygen species, see Oxidative stress

Red blood cell (RBC), see also Anemia lifespan
determination
carbon monoxide breath testing 252, 253
chromium-51 labeling 252
effects on erythropoietin-stimulating agent therapy 250–252
overview 248, 249
pure red cell aplasia with erythropoiesis-stimulating agents 243, 244
survival in renal failure 249
Renal osteodystrophy, definition 224
RISCAVID Study 187, 188
Secondary hyperparathyroidism (SHPT)
control 214, 229, 230, 235–238
pathophysiology 234, 235
Sevelamer
hyperphosphatemia control 227, 228
secondary hyperparathyroidism control 236
Sodium
consequences of sodium excess and overhydration 102–104
dialysate concentration 7, 8
conductivity kinetic modeling 8, 9
modulation of overhydration 104–106
Soy, diet effects on inflammation 80, 81
Statins, Dialysis Outcomes and Practice Patterns Study findings 51, 52
Thrombectomy, vascular access stenosis 33, 34
Treatment time, see Hemodialysis treatment time
Ultrafiltration (UF) rate, treatment time considerations 156–158
Ultrasonography
arteriovenous fistula blood flow surveillance 18, 19
preoperative fistula evaluation arterial assessment 25, 26
venous assessment 27
vascular calcification 226, 227
Urea distribution volume, body mass index relationship 112, 113
Uremia, definition 125
Uremic retention complexity 126, 127
solute 125
Uremic syndrome, definition 125
Uremic toxicity
assessment in vitro 127, 128
definition 125
HEMO Study 128, 129
Vascular access, see also Arteriovenous fistula; Central venous catheter online hemodiafiltration 193
percutaneous balloon angioplasty for stenosis 31–33
thrombectomy 33, 34
tunneled hemodialysis catheter procedures 34, 35
Vascular calcification, see Cardiovascular disease; Chronic kidney disease-mineral and bone disorder
Vitamin C, diet effects on inflammation 79
Vitamin D
analsogs in secondary
hyperparathyroidism control 229, 230, 237, 238
calcidiol as chronic kidney disease-mineral and bone disorder biomarker 225
deficiency in insulin resistance and chronic kidney disease 140, 141
Vitamin E
anemia studies 93–95
dialysis membrane coating clinical studies 92
mechanisms of action 92, 93
synthetic membrane biocompatibility 96
dietary supplementation 90–92
low-density lipoprotein oxidation inhibition 90
Water treatment
clinical benefits 4, 5
contaminant limits 2
distribution loop 2–4
prospects 5
technology 2, 5
Whole-body impedance spectroscopy (BCM)
dry weight assessment 117, 118
model description and validation 115–117